Holen Sie sich die Stockscreener-App
131.69
0.69%
0.90
Schlusskurs vom Vortag:
$130.79
Offen:
$131.825
24-Stunden-Volumen:
2.91M
Relative Volume:
1.82
Marktkapitalisierung:
$9.13B
Einnahmen:
$2.90B
Nettoeinkommen (Verlust:
$302.80M
KGV:
30.65
EPS:
4.2965
Netto-Cashflow:
$387.80M
1W Leistung:
-3.26%
1M Leistung:
-11.10%
6M Leistung:
-35.54%
1J Leistung:
-57.82%
1-Tages-Spanne:
$128.01
$132.53
1-Wochen-Bereich:
$128.01
$135.40
52-Wochen-Spanne:
$126.40
$354.88
Insulet Corp Stock (PODD) Company Profile
Firmenname
Insulet Corp
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
131.69 | 9.44B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
97.50 | 168.71B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-04-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2026-01-27 | Fortgesetzt | TD Cowen | Hold |
| 2026-01-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-19 | Hochstufung | UBS | Neutral → Buy |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corp Aktie (PODD) Neueste Nachrichten
Insulet Corporation (PODD) Stock Forecasts - Yahoo Finance
Important Notice to Long-Term Shareholders of Beta Bionics, - GlobeNewswire
A tubeless insulin pump maker will report results before markets open Nov. 4. - Stock Titan
What Is Changing for Insulet (NASDAQ:PODD)? - Kalkine Media
Insulet Corporation (PODD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insulet Corp. stock outperforms competitors despite losses on the day - MarketWatch
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
38 life sciences companies land $40M in tax incentives for 1,644 Mass. jobs - The Business Journals
Why is Insulet stock sliding today? - Investing.com
Insulet Sees Emerging Headwinds From New Market Entrants in 2027, 2028, Oppenheimer Says - marketscreener.com
Insulet Corp Lobbyists, 2025 - OpenSecrets
Insulet (PODD) Stock May Trade At A Discount To Fair Value - Yahoo Finance
PODD5061895 Bond Profile: Coupon and Redemption - TradingView
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum - Yahoo Finance
Transcript : Insulet Corporation Presents at Bernstein Insights - marketscreener.com
Insulet at Bernstein healthcare forum: growth, retention and new AID push - Investing.com
How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks? - Barchart.com
Insulet (PODD) Refinances $475 Million Term Loans and Expands Re - gurufocus.com
Insulet Reprices $475 Million Term Loans, Expands Revolver to $750 Million in Credit Amendment - TradingView
Insulet (PODD) cuts interest margins on $475M loan and expands credit access - Stock Titan
Insulet Corporation Amends And Increases Credit Agreement, Refinances $475 Million Term Loans, And Expands Revolving Credit Facility To $750 Million - marketscreener.com
Insulet stock gains as Bank of America stake and guidance highlight upside potential - AD HOC NEWS
Insulet Corporation(NasdaqGS: PODD) dropped from FTSE All-World Index - marketscreener.com
Insulet stock heads into the open after a modest September 18, 2026 gain - AD HOC NEWS
Insulet stock gains support from Bank of America stake and strong Q1 2026 figures - AD HOC NEWS
Insulet Stock Price Forecast. Should You Buy PODD? - StockInvest.us
The maker of Omnipod will speak at a healthcare forum Sept. 24 - Stock Titan
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum - Yahoo Finance
The largest med-device firms in Mass. collectively increased revenue in 2025 - The Business Journals
Insulet Corporation (PODD) Adopts Nonqualified Deferred Compensa - GuruFocus
BCSM Exits Insulet Corporation (PODD), Maintains Watchlist Status - Yahoo Finance
Insulet stock heads into the open after a modest decline - AD HOC NEWS
Insulet Faces Class Action Lawsuit Over Product Safety Issues - Intellectia AI
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Important Notice to Long-Term Shareholders of FuelCell - GlobeNewswire
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
Insulet Weighs Major Acton Expansion as State Offers $40M in Incentives - Boston Real Estate Times
Grabar Law probes Bloom Energy, Cogent, Insulet, Primoris for fiduciary breaches - scanx.trade
Insulet Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Insulet Corp (PODD) Shares Fall 3.1% -- What GF Score of 77 Tells Investors - GuruFocus
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Insulet at Wells Fargo conference: guidance cut meets long-term optimism - investing.com
Is Insulet Corp (PODD) a Bargain After 3.5% Drop? GF Value Says Undervalued - GuruFocus
Insulet Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Why Insulet (PODD) Stock Is Down Today - Quiver Quantitative
State offers record $40M package to keep medical device company in Mass. - NBC Boston
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now? - Yahoo Finance
Artisan Sold Insulet (PODD) Due to Competition Concerns - Yahoo Finance
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report? - Yahoo Finance
Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks - Yahoo Finance
Insulet (PODD) Stock May Be 40% Undervalued On Fair Value Grounds - Yahoo Finance
Finanzdaten der Insulet Corp-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insulet Corp-Aktie (PODD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| STONESIFER TIMOTHY C. | Director |
Jun 03 '26 |
Buy |
143.51 |
2,790 |
400,393 |
9,041 |
| BORIO LUCIANA | Director |
Jun 03 '26 |
Sale |
143.27 |
418 |
59,887 |
4,329 |
| WEATHERMAN ELIZABETH H | Director |
Jun 03 '26 |
Buy |
144.20 |
3,450 |
497,490 |
10,352 |
0.26%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):